close
References
  1. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6(3-4):84-105.
  2. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496-22512.
  3. Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9(48):28989-29006.
  4. McDougall AR, Tolcos M, Hooper SB, Cole TJ, Wallace MJ. Trop2: from development to disease. Dev Dyn. 2015;244(2):99-109.
  5. Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. Onco Targets Ther. 2019;12:1781-1790.
  6. Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222-233.
  7. Zeng P, Chen MB, Zhou LN, Tang M, Liu CY, Lu PH. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:33658.
  8. Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017;8(17):28725-28735.
  9. Jiang A, Gao X, Zhang D, Zhang L, Lu H. Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma. Oncol Lett. 2013;6(2):375-380.
  10. Economopoulou P, Mountzios G. The emerging treatment landscape of advanced non-small cell lung cancer. Ann Transl Med. 2018;6(8):138.
  11. Gerber DE. The IASLC Lung Cancer News. Antibody–drug conjugates in NSCLC: complexities, challenges, and potential. Published November 12, 2019. Accessed June 24, 2020. www.lungcancernews.org/2019/11/12/antibody-drug-conjugates-in-nsclc-complexities-challenges-and-potential.
  12. The ASCO Post. Sacituzumab govitecan receives fast track designation for non–small cell lung cancer therapy. Updated May 21, 2015. Accessed June 24, 2020. www.ascopost.com/News/27645.
  13. US Food and Drug Administration. FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer. April 22, 2020. Accessed June 26, 2020. www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sacituzumab-govitecan-hziy-metastatic-triple-negative-breast-cancer.
  14. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741-751.
  15. Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35(24):2790-2797.
  16. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35(19):2141-2148.
  17. Lisberg AE, Sands J, Shimizu T, et al. Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2020;38(15):9619.
  18. Okajima D, Yasuda S, Yokouchi Y, et al. Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd. J Clin Oncol. 2018;36(15):e24206.
  19. ClinicalTrials.gov. A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (TROPICS-03). Updated March 25, 2020. Accessed June 24, 2020. https://clinicaltrials.gov/ct2/show/NCT03964727.
  20. Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21(17):3870-3878.
  21. ClinicalTrials.gov. First-in-Human Study of DS-1062a for Advanced Solid Tumors. Updated July 8, 2020. Accessed September 8, 2020. https://clinicaltrials.gov/ct2/show/NCT03401385.
  22. ClinicalTrials.gov. Rollover Study in Subjects With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan. Updated August 14, 2020. Accessed September 8, 2020. https://clinicaltrials.gov/ct2/show/NCT04319198.
  23. Daiichi Sankyo. Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDAź (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer. Accessed June 26, 2020.
  24. US Food and Drug Administration. Sacituzumab Govitecan Prescribing Information. Accessed June 26, 2020. www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761115Orig1s000TOC.cfm.
  25. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006;17(3):372-379.
  26. US Food and Drug Administration. Trastuzumab Deruxtecan Prescribing Information. Accessed June 29, 2020. www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf.